-
Esketamine, sold
under the
brand names Spravato (for depression) and
Ketanest (for anesthesia)
among others, is the S(+)
enantiomer of ketamine. It is...
- the (R)-(−)
enantiomer of ketamine.
Similarly to
racemic ketamine and
esketamine, the S(+)
enantiomer of ketamine,
arketamine is
biologically active; however...
- an
atypical agent in that it
appears not to do this. In
August 2020,
esketamine (JNJ-54135419) was
approved by the U.S. Food and Drug
Administration (FDA)...
-
ketamine –
esketamine commercially sold as
Spravato – was
approved as an
antidepressant by the
European Medicines Agency in 2019.
Esketamine was approved...
- of ketamine, but
appear to be as
effective as
esketamine in its
potency and duration.
Unlike esketamine, (S)-norketamine does not
appear to significantly...
-
taken by mouth. The drug is a
novel esketamine analogue and
conjugate that acts as a
prodrug of
esketamine.
Esketamine, and by
extension XW10508, is an NMDA...
-
receptor positive allosteric modulator –
approved for
postpartum depression Esketamine (Spravato) – non-competitive NMDA
receptor antagonist,
other actions Gepirone...
- Food and Drug
Administration (FDA)
first approved the use of
intranasal esketamine (Spravato)—an
enantiomer of ketamine—for the use of ketamine-derived therapy...
- disorder, and
major depressive disorder. Spravato, a
nasal spray form of
esketamine, was
approved by the FDA in 2019 for use in treatment-resistant depression...
-
possibility of more
targeted and less
invasive interventions.
Ketamine and
Esketamine: Ketamine, an anesthetic, has
shown rapid antidepressant effects in patients...
